|
+8
|
Biopharma ER?
|
2h |
|
+15
|
Built a desktop valuation app (DCF / DDM / reverse DCF) so I'd stop rebuilding Excel models for every pitch — would value some ER feedback
|
2h |
|
0
|
JPMorgan - Salary & Bonus - Investment Banking |
3h |
|
+38
|
Are any ER juniors actually happy?
|
8h |
|
+7
|
Why hire an equity analyst if AI can write the reports
|
1d |
|
0
|
MLP Equities Analyst Program Update
|
2d |
|
|
|
+114
|
Calling All Former ER: Where Did You Go?
|
2d |
|
+18
|
Former Pharma scientist with sell-side biotech ER experience — interview processes keep stalling, what am I missing
|
4d |
|
0
|
Helaba Hessische Landesbank - Review - Equity Research |
5d |
|
0
|
I truly don’t know what to do
|
6d |
|
+12
|
Started ER Internship, Reconsidering: Exit Opps?
|
6d |
|
0
|
Gabelli Asset Management - Review - Equity Research |
1w |
|
0
|
Gabelli Asset Management - Salary & Bonus - Equity Research |
1w |
|
0
|
Insurance investing conferences?
|
1w |
|
+32
|
Does anyone else find it very difficult to take vacations in ER?
|
1w |
|
+10
|
PayPal (PYPL): Why Is the Market Valuing PayPal Like a Low-Growth Company Despite Strong Free Cash Flow?
|
1w |
|
0
|
Resources to Find Info on Modeling a Biotech Company
|
1w |
|
+13
|
ER--Unusually long reference checks post-superday
|
1w |
|
+18
|
ER - Intern and Full Time QBank Technical Questions
|
1w |
|
0
|
Rising Senior in ER feeling lost/FT advice
|
1w |
|
0
|
GfK Boutique Research - Review - NA |
1w |
|
|
|
0
|
GfK Boutique Research - Salary & Bonus - NA |
1w |
|
+16
|
Intel (INTC): My Bull Case Still Doesn't Justify the Current Stock Price
|
1w |
|
0
|
JPM Equity Research SA27
|
1w |
|
+11
|
Thoughts on boutique ER firm opportunity and options afterwards
|
1w |
|
0
|
JPM Equity Research SA27?
|
1w |
|
0
|
RBC Royal Bank of Canada - Review - Energy |
1w |
|
0
|
RBC Royal Bank of Canada - Salary & Bonus - Energy |
1w |
|
+9
|
Rising Sophomore clueless about recruiting timeline
|
2w |
|
0
|
William Blair - Review - Equity Research |
2w |
|
+7
|
Irenic Latest Views?
|
2w |
|
0
|
Fidelity Investments - Interview - NA |
2w |
|
0
|
Cantor Fitzgerald - Interview - Pharmaceuticals |
2w |
|
+14
|
Rising junior at semi-target, fumbled sophomore recruiting — how cooked am I really?
|
2w |
|
+9
|
Is equity research dead? If not, what aspects are still viable?
|
3w |
|
+40
|
Lowest Comp You'd Take For Lead Coverage
|
3w |
|
+8
|
What is the best path for me as MBA student to HF
|
1mo |
|
+9
|
CC student, help choose schools
|
1mo |
|
0
|
Fidelity International - Review - Equity Research |
1mo |
|
+16
|
DB ER?
|
1mo |
|
0
|
Stifel Financial - Salary & Bonus - Power |
1mo |
|
0
|
Morgan Stanley - Interview - Equity Capital Markets |
1mo |
|
0
|
Wolfe Research - Review - NA |
1mo |
|
+18
|
ER Pulse Check... How We Doing?
|
1mo |
|
+17
|
Equity Research Today: What skills are actually most valuable for entry-level analysts?
|
1mo |
|
+20
|
Article: UBS: The Fragile Facade of a Post-Merger Powerhouse
|
1mo |
|
+66
|
Best B-school for Equity Research
|
1mo |
|
0
|
Do these basically kills the need of an Sell Side associate?
|
1mo |
|
0
|
Wells Fargo and Company - Interview - NA |
1mo |
|
+6
|
GS Off-Cycle GIR
|
1mo |
|
0
|
Wasatch Global Investors - Interview - Generalist |
1mo |
|
0
|
Credit Suisse - Review - Equity Research |
1mo |
|
0
|
UBS AG - Salary & Bonus - Equity Research |
1mo |
|
0
|
Amazon - Review - Risk |
1mo |
|
0
|
Amazon - Salary & Bonus - Risk |
1mo |
|
+37
|
MD hates me, what do I do?
|
1mo |
|
0
|
Kempen - Salary & Bonus - Equities |
1mo |
|
+10
|
Automating Equity Research Workflows — From 2–3 Hours to ~20 Minutes
|
1mo |
|
+12
|
Bored on the buyside
|
1mo |
|
0
|
KeyBanc Capital Markets - Salary & Bonus - Consumer - Retail |
1mo |
|
0
|
KeyBanc Capital Markets - Review - NA |
1mo |
|
0
|
JC Clark - Review - Generalist |
1mo |
|
+3
|
Power & utilities primer / initiation?
|
1mo |
|
+15
|
ER Case Study guidance
|
1mo |
|
+9
|
Notes from JBL's Q2 Earnings Call: Margins, Capex, and the FY27 Bridge
|
2mo |
|
+15
|
ER 27 Timeline
|
2mo |
|
+12
|
Texas ER work life?
|
2mo |
|
0
|
Deriving Fixed/Variable Costs with Limited Disclosure
|
2mo |
|
+9
|
IB SA -> ER
|
2mo |
|
0
|
KeyBanc Capital Markets - Interview - Industrials |
2mo |
|
0
|
Emerald Asset Management - Review - Consumer - Retail |
2mo |
|
0
|
Emerald Asset Management - Salary & Bonus - Consumer - Retail |
2mo |
|
+9
|
Ford's CEO and CFO sounded exactly the same on the Q4 call. That's weird, right?
|
2mo |
|
+4
|
Best ER firms?
|
2mo |
|
0
|
TD Securities - Review - Technology, Media and Telecom (TMT) |
2mo |
|
0
|
TD Bank - Salary & Bonus - Technology, Media and Telecom (TMT) |
2mo |
|
0
|
SIG 2026 Full-time ER
|
2mo |
|
+9
|
Let go from LO cross-asset seat. How to position next move?
|
2mo |
|
0
|
ESG Research Analyst > Investment Analyst in an ESG fund
|
2mo |
|
0
|
RBC Royal Bank of Canada - Review - Technology, Media and Telecom (TMT) |
2mo |
|
0
|
RBC Royal Bank of Canada - Salary & Bonus - Technology, Media and Telecom (TMT) |
2mo |
|
+1
|
ER (London) BB Comp 2026?
|
2mo |
|
+9
|
Bloomberg Intelligence vs Sell-Side Equity Research → Buyside Path?
|
2mo |
|
+16
|
Looking for help in choosing London Master’s degree
|
2mo |
|
+32
|
Q&A New Mentor | Senior Buyside Analyst – Equity Research, Healthcare Coverage & Breaking into the Buyside
|
2mo |
|
+4
|
Industry landscapes and themes
|
2mo |
|
0
|
Gilder Gagnon Howe
|
2mo |
|
+9
|
Analyzing Distribution Patterns: Form 4 Outflows and Foundry Cycles
|
2mo |
|
+9
|
are in-person channel checks for consumer companies useful
|
2mo |
|
+3
|
Timeline post case study
|
2mo |
|
0
|
HSBC - Interview - Investment Research |
2mo |
|
+6
|
Good insurance industry ER primer / initiation?
|
2mo |
|
0
|
Janus Henderson Global Investors - Review - Generalist |
2mo |
|
0
|
Janus Henderson Global Investors - Salary & Bonus - Generalist |
2mo |
|
0
|
Mackie Research Capital Corporation - Review - Healthcare |
2mo |
|
0
|
Mackie Research Capital Corporation - Salary & Bonus - Healthcare |
2mo |
|
+44
|
Support Group for ER Associates Working IB Hours
|
2mo |
|
+9
|
Institutional Capital Allocation: Decoding the Macro Shift Through Regulatory Disclosures
|
2mo |
or Want to Sign up with your social account?